Why Hinge Health (HNGE) is on investors’ radar

Hinge Health (HNGE) has been drawing attention after recent trading, with the stock last closing at US$55.25 and posting double digit gains over the past month and past 3 months.

For investors tracking digital health, the company’s roughly US$4.3b market cap and annual revenue of US$646.34m, alongside a reported net loss of US$511.39m, provide context for thinking about risk and potential reward.

The recent 30 day share price return of 24.75% and 90 day share price return of 37.75%, alongside a 1 year total shareholder return of 37.57%, suggest momentum has been building as investors reassess growth prospects against ongoing losses.

If Hinge Health has put digital health back on your watchlist, it may also be worth scanning for other healthcare focused AI opportunities using the 34 healthcare AI stocks

With Hinge Health still loss making but reporting US$646.34m in revenue and trading below analysts’ average price target, investors are asking a key question: is there genuine upside left, or is the market already pricing in future growth?

Most Popular Narrative: 14.1% Undervalued

Hinge Health's most followed valuation narrative pegs fair value at $64.29 per share, above the recent $55.25 close. On that view, the stock screens as undervalued.

Rapid adoption of AI across care delivery and internal operations, including Robin and engineering productivity tools, is increasing clinician throughput and product velocity. This trend may structurally improve operating leverage and net margins over time.

Curious what earnings path and margin shift need to show up for that fair value to hold up? The narrative leans on faster revenue compounding, rising profitability and a steeper valuation multiple than many healthcare stocks usually carry.

Result: Fair Value of $64.29 (UNDERVALUED)

However, you also need to weigh risks, such as pressure on employer budgets that could curb demand or any regulatory pushback that slows Hinge Health's AI rollout.

Another way to look at Hinge Health

While the popular narrative points to a fair value of $64.29 and an undervalued stock, the current 6.6x P/S ratio is far richer than the US Healthcare industry average of 1.2x and peer average of 4x. It is also still above a 6.2x fair ratio, which raises the question of how comfortable you are paying that premium.

Next Steps

With sentiment this mixed, it makes sense to act quickly, review the facts for yourself, and see why some investors are focusing on 4 key rewards

Looking for more investment ideas?

Do not stop at a single stock. Use the Simply Wall St screener to spot fresh opportunities that match how you like to invest before others move first.

• Target potential mispriced opportunities by scanning 48 high quality undervalued stocks that combine quality with appealing valuations.
• Seek steadier portfolio anchors with the 69 resilient stocks with low risk scores and focus on companies scoring well on risk metrics.
• Hunt for early stage potential with the 25 elite penny stocks with strong financials and see which smaller companies match your risk and return preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.